Valuation: Indivior

Market Cap 4.94B 4.34B 4.04B 3.7B 6.96B 476B 7.07B 47.92B 18.72B 234B 18.55B 18.15B 809B P/E 2026 *
12.8x
P/E 2027 * 11.2x
Enterprise Value 5B 4.39B 4.08B 3.74B 7.03B 481B 7.14B 48.45B 18.93B 237B 18.75B 18.35B 818B EV / Sales 2026 *
3.96x
EV / Sales 2027 * 3.46x
Free-Float
97.23%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 4.94B
+0.86%+1.43%+48.50%+160.39% 1,067B
+1.59%+4.09%+55.34%+53.96% 635B
+0.95%+1.91%+35.91%+81.14% 458B
+1.60%+6.25%+33.95%+29.84% 347B
-0.60%+1.52%+35.68%+39.76% 295B
-0.14%+0.60%+16.17%+17.53% 262B
+0.09%-2.82%-28.29%-41.71% 216B
+1.22%+2.66%+21.87%+59.73% 203B
-1.18%-3.70%+14.23%+66.51% 161B
Average +0.34%+1.33%+25.93%+51.91% 404.78B
Weighted average by Cap. +0.55%+1.95%+35.81%+77.68%

Financials

2026 *2027 *
Net sales 1.26B 1.11B 1.03B 944M 1.77B 121B 1.8B 12.22B 4.78B 59.66B 4.73B 4.63B 206B 1.31B 1.15B 1.07B 984M 1.85B 126B 1.88B 12.73B 4.97B 62.14B 4.93B 4.82B 215B
Net income 414M 364M 339M 311M 584M 39.91B 593M 4.02B 1.57B 19.62B 1.56B 1.52B 67.85B 473M 415M 386M 354M 666M 45.54B 676M 4.59B 1.79B 22.39B 1.78B 1.74B 77.41B
Net Debt 54.5M 47.87M 44.52M 40.85M 76.75M 5.25B 77.94M 529M 207M 2.58B 205M 200M 8.92B -403M -354M -329M -302M -568M -38.85B -577M -3.91B -1.53B -19.1B -1.51B -1.48B -66.03B
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-